Abstract:Noncovalent interactions between small-molecule drugs and protein targets assume a pivotal role in drug design. Moreover, the design of covalent inhibitors, forming covalent bonds with amino acid residues, requires rational reactivity for their covalent warheads, presenting a key challenge as well. Understanding the intricacies of these interactions provides a more comprehensive understanding of molecular binding mechanisms, thereby guiding the rational design of potent inhibitors. In this study, we adopted the fragment-based drug design approach, introducing a novel methodology to extract noncovalent and covalent fragments according to distinct three-dimensional (3D) interaction modes from noncovalent and covalent compound libraries. Additionally, we systematically replaced existing ligands with rational fragment substitutions, based on the spatial orientation of fragments in 3D space. Furthermore, we adopted a molecular generation approach to create innovative covalent inhibitors. This process resulted in the recombination of a noncovalent compound library and several covalent compound libraries, constructed by two commonly encountered covalent amino acids: cysteine and serine. We utilized noncovalent ligands in KLIFS and covalent ligands in CovBinderInPDB as examples to recombine noncovalent and covalent libraries. These recombined compound libraries cover a substantial portion of the chemical space present in the original compound libraries and exhibit superior performance in terms of molecular scaffold diversity compared to the original compound libraries and other 11 commercial libraries. We also recombined BTK-focused libraries, and 23 compounds within our libraries have been validated by former researchers to possess potential biological activity. The establishment of these compound libraries provides valuable resources for virtual screening of covalent and noncovalent drugs targeting similar molecular targets.

Covalent hits and where to find them

Hit me with your best shot: Integrated hit discovery for the next generation of drug targets

Compound Libraries: Recent Advances and Their Applications in Drug Discovery.

Advances in covalent drug discovery

Covalent fragment-based drug discovery for target tractability

Advanced technologies for screening and identifying covalent inhibitors

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation

DNA-Encoded Library Technology─A Catalyst for Covalent Ligand Discovery

Design of a Lead-Like Cysteine-Targeting Covalent Library and the Identification of Hits to Cys55 of Bfl-1

Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening

Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery

Increasing the Odds of Drug Hit Identification by Screening Against Receptor Homologs?

Constructing Innovative Covalent and Noncovalent Compound Libraries: Insights from 3D Protein–Ligand Interactions

Application of covalent modality in proximity-induced drug pharmacology: Early development, current strategy, and feature directions

High-Throughput Covalent Modifier Screening with Acoustic Ejection Mass Spectrometry

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and Targets

The Screening Compound Collection: A Key Asset for Drug Discovery

Structure-Based Virtual Screening of Chemical Libraries for Drug Discovery

Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation

Landscape of In Silico Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery

CovalentInDB 2.0: an Updated Comprehensive Database for Structure-Based and Ligand-Based Covalent Inhibitor Design and Screening.